Trial · NCT02567656
Adverse events156
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 156
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Alanine aminotransferase increased | Investigations | Dose escalation_Cohort 1_200 mg | 1 | 4 | 2 |
| other | Alanine aminotransferase increased | Investigations | Dose escalation_Cohort 2_400 mg | 0 | 4 | 0 |
| other | Alanine aminotransferase increased | Investigations | Dose escalation_Cohort 3_800 mg (Fasting) | 2 | 5 | 3 |
| other | Alanine aminotransferase increased | Investigations | Dose escalation_Cohort 4_800 mg (Fed) | 3 | 6 | 3 |
| other | Alanine aminotransferase increased | Investigations | Dose expansion_PTCL_800 mg (Fasting) | 4 | 19 | 5 |
| other | Alanine aminotransferase increased | Investigations | Dose expansion_CTCL_800 mg (Fasting) | 8 | 20 | 13 |
| other | Aspartate aminotransferase increased | Investigations | Dose escalation_Cohort 1_200 mg | 1 | 4 | 3 |
| other | Aspartate aminotransferase increased | Investigations | Dose escalation_Cohort 2_400 mg | 0 | 4 | 0 |
| other | Aspartate aminotransferase increased | Investigations | Dose escalation_Cohort 3_800 mg (Fasting) | 2 | 5 | 2 |
| other | Aspartate aminotransferase increased | Investigations | Dose escalation_Cohort 4_800 mg (Fed) | 3 | 6 | 10 |
| other | Aspartate aminotransferase increased | Investigations | Dose expansion_PTCL_800 mg (Fasting) | 4 | 19 | 5 |
| other | Aspartate aminotransferase increased | Investigations | Dose expansion_CTCL_800 mg (Fasting) | 8 | 20 | 15 |
| other | Diarrhoea | Gastrointestinal disorders | Dose escalation_Cohort 1_200 mg | 1 | 4 | 2 |
| other | Diarrhoea | Gastrointestinal disorders | Dose escalation_Cohort 2_400 mg | 0 | 4 | 0 |
| other | Diarrhoea | Gastrointestinal disorders | Dose escalation_Cohort 3_800 mg (Fasting) | 1 | 5 | 1 |
| other | Diarrhoea | Gastrointestinal disorders | Dose escalation_Cohort 4_800 mg (Fed) | 1 | 6 | 1 |
| other | Diarrhoea | Gastrointestinal disorders | Dose expansion_PTCL_800 mg (Fasting) | 2 | 19 | 2 |
| other | Diarrhoea | Gastrointestinal disorders | Dose expansion_CTCL_800 mg (Fasting) | 7 | 20 | 8 |
| other | Fatigue | General disorders | Dose escalation_Cohort 1_200 mg | 0 | 4 | 0 |
| other | Fatigue | General disorders | Dose escalation_Cohort 2_400 mg | 1 | 4 | 1 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02567656/events